EP1351930A2 - Protease inhibitors - Google Patents
Protease inhibitorsInfo
- Publication number
- EP1351930A2 EP1351930A2 EP00977056A EP00977056A EP1351930A2 EP 1351930 A2 EP1351930 A2 EP 1351930A2 EP 00977056 A EP00977056 A EP 00977056A EP 00977056 A EP00977056 A EP 00977056A EP 1351930 A2 EP1351930 A2 EP 1351930A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- disease
- formula
- cathepsin
- protease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title description 6
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 95
- 201000010099 disease Diseases 0.000 claims abstract description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 32
- 102000005927 Cysteine Proteases Human genes 0.000 claims abstract description 28
- 108010005843 Cysteine Proteases Proteins 0.000 claims abstract description 28
- 108090000625 Cathepsin K Proteins 0.000 claims abstract description 22
- 206010065687 Bone loss Diseases 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 239000012453 solvate Substances 0.000 claims abstract description 4
- 102000004171 Cathepsin K Human genes 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 39
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 28
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 19
- 239000004365 Protease Substances 0.000 claims description 14
- 108091005804 Peptidases Proteins 0.000 claims description 12
- 208000001132 Osteoporosis Diseases 0.000 claims description 9
- 210000000845 cartilage Anatomy 0.000 claims description 9
- 239000011159 matrix material Substances 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 208000007565 gingivitis Diseases 0.000 claims description 7
- 230000001590 oxidative effect Effects 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- 230000015556 catabolic process Effects 0.000 claims description 6
- 238000006731 degradation reaction Methods 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000007800 oxidant agent Substances 0.000 claims description 6
- 201000001245 periodontitis Diseases 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 102000012479 Serine Proteases Human genes 0.000 claims description 4
- 108010022999 Serine Proteases Proteins 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- YMZTUCZCQMQFMK-UHFFFAOYSA-N 3-methyl-1-benzofuran-2-carboxylic acid Chemical compound C1=CC=C2C(C)=C(C(O)=O)OC2=C1 YMZTUCZCQMQFMK-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004811 liquid chromatography Methods 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 18
- 230000005764 inhibitory process Effects 0.000 abstract description 9
- 230000008355 cartilage degradation Effects 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000002253 acid Substances 0.000 description 24
- 102100024940 Cathepsin K Human genes 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 210000000988 bone and bone Anatomy 0.000 description 16
- -1 osteocalcm Proteins 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 102000035195 Peptidases Human genes 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 102000005600 Cathepsins Human genes 0.000 description 9
- 108010084457 Cathepsins Proteins 0.000 description 9
- 210000002997 osteoclast Anatomy 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 8
- 208000006386 Bone Resorption Diseases 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108090000526 Papain Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 230000024279 bone resorption Effects 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 229940055729 papain Drugs 0.000 description 6
- 235000019834 papain Nutrition 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 208000024693 gingival disease Diseases 0.000 description 5
- 150000002576 ketones Chemical class 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 208000010191 Osteitis Deformans Diseases 0.000 description 4
- 208000027868 Paget disease Diseases 0.000 description 4
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- OSLGKRDOEMLAJV-UHFFFAOYSA-N benzyl n-prop-2-enylcarbamate Chemical compound C=CCNC(=O)OCC1=CC=CC=C1 OSLGKRDOEMLAJV-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 150000002118 epoxides Chemical class 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 208000027202 mammary Paget disease Diseases 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- LPNANKDXVBMDKE-UHFFFAOYSA-N 5-bromopent-1-ene Chemical compound BrCCCC=C LPNANKDXVBMDKE-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010020584 Hypercalcaemia of malignancy Diseases 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 3
- 208000029725 Metabolic bone disease Diseases 0.000 description 3
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- UGUUDTWORXNLAK-UHFFFAOYSA-N azidoalcohol Chemical compound ON=[N+]=[N-] UGUUDTWORXNLAK-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 208000008750 humoral hypercalcemia of malignancy Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 201000006938 muscular dystrophy Diseases 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- ZJLMKPKYJBQJNH-UHFFFAOYSA-N propane-1,3-dithiol Chemical compound SCCCS ZJLMKPKYJBQJNH-UHFFFAOYSA-N 0.000 description 3
- 201000004409 schistosomiasis Diseases 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101710177066 Cathepsin O Proteins 0.000 description 2
- 241000222716 Crithidia Species 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 2
- 241000233872 Pneumocystis carinii Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 210000004268 dentin Anatomy 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- SWIOGPHKKZUDIC-UHFFFAOYSA-L dichlororuthenium(2+) Chemical compound Cl[Ru+2]Cl SWIOGPHKKZUDIC-UHFFFAOYSA-L 0.000 description 2
- 150000001993 dienes Chemical class 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- FBPINGSGHKXIQA-UHFFFAOYSA-N 2-amino-3-(2-carboxyethylsulfanyl)propanoic acid Chemical compound OC(=O)C(N)CSCCC(O)=O FBPINGSGHKXIQA-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000761509 Homo sapiens Cathepsin K Proteins 0.000 description 1
- 101000910979 Homo sapiens Cathepsin Z Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001484259 Lacuna Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 102000009890 Osteonectin Human genes 0.000 description 1
- 108010077077 Osteonectin Proteins 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000006270 Proton Pumps Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940124325 anabolic agent Drugs 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- ZZGDDBWFXDMARY-SVBPBHIXSA-N benzyl n-[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate Chemical compound C([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC1=CC=2OC(=O)C=C(C=2C=C1)C)NC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 ZZGDDBWFXDMARY-SVBPBHIXSA-N 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000000339 bright-field microscopy Methods 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 210000003541 chondroclast Anatomy 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 239000002223 garnet Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 150000002373 hemiacetals Chemical class 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022932 ruffle assembly Effects 0.000 description 1
- RADGOBKLTHEUQO-UHFFFAOYSA-N ruthenium(4+) Chemical compound [Ru+4] RADGOBKLTHEUQO-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates to a novel deuterated 4-am ⁇ no-azepan-3-one protease inhibitor.
- This compound is particularly an inhibitor of cysteine and senne proteases, more particularly an inhibitor of cysteine proteases.
- the compound of this invention even more particularly inhibits cysteine proteases of the papain superfamily, and yet more particularly cysteine proteases of the cathepsin family.
- this invention relates to a compound which inhibits cathepsin K.
- Such compound is particularly useful for treating diseases in which cysteine proteases are implicated, especially diseases of excessive bone or cartilage loss, e.g., osteoporosis, periodontitis, and arthntis
- Cathepsin K is a member of the family of enzymes which are part of the papain superfamily of cysteine proteases. Cathepsins B, H, L, N and S have been described in the literature. Recently, cathepsin K polypeptide and the cDNA encoding such polypeptide were disclosed in U.S. Patent No. 5,501,969 (called cathepsin O therein). Cathepsin K has been recently expressed, purified, and charactenzed. Bossard, M. J., et al., (1996) J Biol Chem.
- Cathepsin K has been vanously denoted as cathepsin O, cathepsin X or cathepsin 02 in the literature.
- the designation cathepsin K is considered to be the more appropnate one (name assigned by Nomenclature Committee of the International Union of Biochemistry and Molecular Biology)
- Cathepsins of the papam superfamily of cysteine proteases function m the normal physiological process of protein degradation in animals, including humans, e.g., in the degradation of connective tissue. However, elevated levels of these enzymes in the body can result in pathological conditions leading to disease.
- cathepsins have been implicated in various disease states, including but not limited to, infections by pneumocystis carinii, trypsanoma cruzi, trypsanoma brucei brucei, and Crithidia fusiculata; as well as m schistosomiasis malaria, tumor metastasis, metachromatic leukodystrophy, muscular dystrophy, amytrophy, and the like.
- WO 94/04172 published on March 3, 1994
- references cited therein See also European Patent Application EP 0 603 873 Al, and references cited therein.
- Two bacterial cysteine proteases from P. gingivalhs, called gingipams have been implicated in the pathogenesis of gingivitis Potempa, J , et al. (1994) Perspectives in Drug Discovery and Design, 2, 445- 458.
- Bone is composed of a protein matrix in which spmdle- or plate-shaped crystals of hydroxyapatite are incorporated Type I Collagen represents the major structural protein of bone compnsing approximately 90% of the structural protein The remaining 10% of matrix is composed of a number of non-collagenous proteins, including osteocalcm, proteoglycans, osteopontin, osteonectin, thrombospondm, fibronectin, and bone sialoprotem. Skeletal bone undergoes remodeling at discrete foci throughout life These foci, or remodeling units, undergo a cycle consisting of a bone resorption phase followed by a phase of bone replacement
- Bone resorption is carried out by osteoclasts, which are multinuclear cells of hematopoietic lineage.
- the osteoclasts adhere to the bone surface and form a tight sealing zone, followed by extensive membrane ruffling on their apical (i.e., resorbing) surface
- cathepsm K may provide an effective treatment for diseases of excessive bone loss, including, but not limited to, osteoporosis, gingival diseases such as gingivitis and periodontitis, Paget's disease, hypercalcemia of malignancy, and metabolic bone disease.
- Cathepsin K levels have also been demonstrated to be elevated in chondroclasts of osteoarthntic synovium
- selective inhibition of cathepsin K may also be useful for treating diseases of excessive cartilage or matnx degradation, including, but not limited to, osteoarthntis and rheumatoid arthntis.
- Metastatic neoplastic cells also typically express high levels of proteolytic enzymes that degrade the surrounding matrix
- selective inhibition of cathepsm K may also be useful for treating certain neoplastic diseases
- a certain novel deuterated compound is a protease inhibitor, most particularly an inhibitor of cathepsin K, and that this compound is useful for treating diseases charactenzed by bone loss, such as osteoporosis and gingival diseases, such as gingivitis and periodontitis, or by excessive cartilage or matrix degradation, such as osteoarthritis and rheumatoid arthritis
- An object of the present invention is to provide a deuterated 4-am ⁇ no-azepan-3-one protease inhibitor, particularly an inhibitor of cysteine and serine proteases More particularly, the present invention relates to such a compound which inhibits cysteine proteases, and yet more particularly cysteine proteases of the papain superfamily Preferably, this invention relates to such a compound which inhibits cysteine proteases of the cathepsin family and most preferably, a compound which inhibits cathepsin K The compound of the present invention is useful for treating diseases which may be therapeutically modified by altering the activity of such proteases
- this invention provides a compound, 3- methylbenzofuran-2-carboxyl ⁇ c acid ⁇ (S)-3-methyl- 1 -[(2,2',4-tn practitionero)-3-oxo- 1 -( 1 -oxy- pynd ⁇ ne-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl ⁇ am ⁇ de, according to Formula I
- this invention provides a pharmaceutical composition compnsmg a compound according to Formula I and a pharmaceutically acceptable carrier
- this invention provides a method of treating diseases m which the disease pathology may be therapeutically modified by inhibiting proteases, such as cysteine and serine proteases
- the method includes treating diseases by inhibiting cysteine proteases, and particularly cysteine proteases of the papain superfamily More particularly, the inhibition of cysteine proteases of the cathepsin family, such as cathepsin K is descnbed
- the compound of this invention is especially useful for treating diseases characterized by bone loss, such as osteoporosis, and gingival diseases, such as gingivitis and periodontitis, or by excessive cartilage or matrix degradation, such as osteoarthritis and rheumatoid arthritis.
- the present invention provides a compound, 3-methylbenzofuran-2-carboxylic acid ⁇ (S)-3-methyl- 1 -[(2,2',4-trideuterio)-3-oxo- 1 -( 1 -oxy-pyridine-2-sulfonyl)-azepan-4- ylcarbamoyl] -butyl ⁇ amide, of Formula (I):
- the present invention includes all hydrates, solvates, complexes, polymorphs and prodrugs of the compound of Formula (I).
- Prodrugs are any covalently bonded compounds which release the active parent drug according to Formula (I) in vivo.
- Prodrugs of the compound of the present invention include ketone derivatives, specifically ketals or hemiketals.
- inventive compound may be used as a racemic mixture, an enantiomerically enriched mixture, or the racemic mixture may be separated using well-known techniques and an individual enantiomer may be used alone.
- each tautomeric form is contemplated as being included within this invention whether existing in equilibrium or predominantly in one form.
- the 7 membered ring compound of the present invention is configurationally more stable at the carbon center alpha to the ketone.
- m- CPBA means .wet ⁇ -chloroperoxybenzoic acid
- Boc means terf-butoxycarbonyl
- EDC means l-(3-d ⁇ methylammopropyl)-3-ethylcarbodnm ⁇ de hydrochlonde
- DMSO means methyl sulfoxide
- TEA means tnethylamine
- Epoxidation of azepme 3 may be effected with standard oxidizing agents common to the art such as -CPBA to provide epoxide 4
- Nucleophilic epoxide nng opening of 4 may be effected with a reagent such as sodium azide to provide the azido alcohol (not shown)
- Reagents and Conditions a.) NaH, 5-bromo- 1 -pentene, DMF; b.) bis(t ⁇ cyclohexylphosphme)benzyhdine ruthenium (IV) dichloride, CH 2 C1 2 : c.) /w-CPBA, CH 2 C1 2 ; d.) NaN,, CH,OH, H 2 0, NH 4 C1; e.) 1 ,3-propanedithiol, TEA, methanol; f.) N-Boc-leucine, EDC, CH 2 C1 2 ; g.) 10% Pd/C, H 2 ; h.) 2-pyridinesulphonyl chlo ⁇ de-N-oxide.
- the intermediate azido alcohol may be reduced to the ammo alcohol 5 under conditions common to the art such as 1 ,3-propanedithiol and tnethylamme m methanol or with t ⁇ phenylphosphine in tetrahydrofuran and water.
- Acylation of 5 may be effected with an acid such as N-Boc-leucine in the presence of a coupling agent such as EDC Removal of the benzyl oxycarbonyl protecting group with hydrogen gas in the presence of 10% Pd/C provides the amine 6
- a coupling agent such as EDC
- EDC electrospray Desorption
- benzyl oxycarbonyl protecting group with hydrogen gas in the presence of 10% Pd/C
- Coupling of 7 with 3-methylbenzofuran-2-carboxyhc acid may be effected with a coupling agent such as EDC to provide intermediate alcohol 8.
- Alcohol 8 may be oxidized with an oxidant such as sulfur t ⁇ oxide pyndine complex in DMSO and tnethylamme to provide the ketone 9 as a mixture of diastereomers.
- an oxidant such as sulfur t ⁇ oxide pyndine complex in DMSO and tnethylamme
- Treatment of ketone 9 with triethylamine in CD ⁇ OD D 2 0 at reflux provides the deuterated analog as a mixture of diastereomers which are separated by
- protective groups generally refers to the Boc, acetyl, benzoyl, Fmoc and Cbz groups and denvatives thereof as known to the art Methods for protection and deprotection, and replacement of an amino protecting group with another moiety are well known.
- Acid addition salts of the compound of Formula (I) are prepared in a standard manner m a suitable solvent from the parent compound and an excess of an acid, such as hydrochloric, hydrobromic, hydrofluoric, sulfunc, phosphoric, acetic, tnfluoroacetic, maleic, succmic or methanesulfonic acid
- an acid such as hydrochloric, hydrobromic, hydrofluoric, sulfunc, phosphoric, acetic, tnfluoroacetic, maleic, succmic or methanesulfonic acid
- novel Intermediate also provides a novel intermediate, 3-methylbenzofuran-2- carboxyhc acid ⁇ (S)-3 -methyl- 1 -[3-hydroxy- 1 -( 1 -oxy-py ⁇ dme-2-sulfonyl)-azepan-4- ylcarbamoyl]-butyl ⁇ am ⁇ de (8-Scheme-l), of Formula (II), useful in the synthesis of the compound of Formula (I) according to Scheme 1
- the present invention provides a process for the synthesis of compounds of Formula (I) comprising the step of oxidizing the appropriate compound of Formula (II) with an oxidant to provide the compound of Formula (I) as a mixture of diastereomers.
- the oxidant is sulfur tnoxide pyndine complex m DMSO and tnethylamme.
- the present invention also provides a process for the synthesis of deuterated compounds of Formula (I) Specifically, when a deuterated isomer is desired, an additional step, following the oxidation step, of deuteratmg the protonated isomer with a deuteratmg agent to provide the deuterated compound of Formula (I) as a mixture of diastereomers is added to the synthesis.
- the deuteratmg agent is CD 3 OD:D 2 0 (10: 1) in tnethylamme.
- the process further comprises the step of separating the diasteromers of Formula
- the present compound of Formula I exhibits superior chiral stability compared to the protonated isomer.
- This invention also provides a pharmaceutical composition which comprises a compound according to Formula (I) and a pharmaceutically acceptable earner, excipient or diluent Accordingly, the compound of Formula (I) may be used in the manufacture of a medicament
- Pharmaceutical compositions of the compound of Formula (I) prepared as hereinbefore described may be formulated as solutions or lyophihzed powders for parenteral administration Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable earner prior to use
- the liquid formulation may be a buffered, isotonic, aqueous solution
- suitable diluents are normal isotonic saline solution, standard 5% dextrose in water, or buffered sodium or ammonium acetate solution
- Such formulation is especially suitable for parenteral administration, but may also be used for oral administration or contained in a metered dose inhaler or ne
- the compound of this invention may also be combined with excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols and molded into a suppository
- the compound of Formula (I) is useful as a protease inhibitor, particularly as an inhibitor of cysteine and serme proteases, more particularly as an inhibitor of cysteine proteases, even more particularly as an inhibitor of cysteine proteases of the papain superfamily, yet more particularly as an inhibitor of cysteine proteases of the cathepsin family, most particularly as an inhibitor of cathepsin K
- the present invention also provides useful compositions and formulations of said compound, including pharmaceutical compositions and formulations of said compound
- the present compound is useful for treating diseases in which cysteine proteases are implicated, including infections by pneumocystis carinii, trypsanoma cruzi, trypsanoma brucei, and Crithidia fusiculata, as well as in schistosomiasis, malana, tumor metastasis, metachromatic leukodystrophy, muscular dystrophy, amytrophy, and especially diseases in which cathepsin K is implicated, most particularly
- Metastatic neoplastic cells also typically express high levels of proteolytic enzymes that degrade the sunounding matrix, and certain tumors and metastatic neoplasias may be effectively treated with the compound of this invention
- the present invention also provides methods of treatment of diseases caused by pathological levels of proteases, particularly cysteine and serine proteases, more particularly cysteine proteases, even more particularly cysteine proteases of the papain superfamily, yet more particularly cysteine proteases of the cathepsin family, which methods comprise admmistenng to an animal, particularly a mammal, most particularly a human in need thereof the compound of the present invention
- the present invention especially provides methods of treatment of diseases caused by pathological levels of cathepsin K, which methods comprise admmistenng to an animal, particularly a mammal, most particularly a human m need thereof, an inhibitor of cathepsin K, including the compound of the present invention
- the present invention particularly provides methods for treating diseases in which cysteine proteases are implicated, including infections by pneumocystis cannn, trypsanoma cruzi, trypsanoma brucei, and Cnthidia fusiculata, as well as in schi
- an effective amount of the compound of Formula (I) is administered to inhibit the protease implicated in a particular condition or disease
- this dosage amount will further be modified according to the type of administration of the compound
- parenteral administration of the compound of Formula (I) is preferred
- An intravenous infusion of the compound m 5% dextrose in water or normal salme, or a similar formulation with suitable excipients, is most effective, although an intramuscular bolus injection is also useful
- the parenteral dose will be about 0.01 to about 100 mg/kg, preferably between 0 1 and 20 mg/kg, in a manner to maintain the concentration of drug in the plasma at a concentration effective to inhibit cathepsin K.
- the compound is administered one to four times daily at a level to achieve a total daily dose of about 0 4 to about 400 mg/kg day.
- the precise amount of the inventive compound which is therapeutically effective, and the route by which such compound is best administered, is readily determined by one of ordinary skill in the art by comparing the blood level of the agent to the concentration required to have a therapeutic effect
- Prodrugs of the compound of the present invention may be prepared by any suitable method Where the prodrug moiety is a ketone functionality, specifically ketals and/or hemiacetals, the conversion may be effected m accordance with conventional methods
- the compound of this invention may also be administered orally to the patient, in a manner such that the concentration of drug is sufficient to inhibit bone resorption or to achieve any other therapeutic indication as disclosed herein.
- a pharmaceutical composition containing the compound is administered at an oral dose of between about 0.1 to about 50 mg/kg in a manner consistent with the condition of the patient Preferably the oral dose would be about 0.5 to about 20 mg/kg No unacceptable toxicological effects are expected when compounds of the present invention are administered in accordance with the present invention
- Standard assay conditions for the determination of kinetic constants used a fluorogemc peptide substrate, typically Cbz-Phe-Arg-AMC, and were determined in 100 mM Na acetate at pH 5 5 containing 20 mM cysteine and 5 mM EDTA Stock substrate solutions were prepared at concentrations of 10 or 20 mM in DMSO with 20 ⁇ M final substrate concentration in the assays. All assays contained 10% DMSO Independent expenments found that this level of DMSO had no effect on enzyme activity or kinetic constants. All assays were conducted at ambient temperature. Product fluorescence (excitation at 360 nM; emission at 460 nM) was monitored with a Perceptive Biosystems Cytofluor II fluorescent plate reader. Product progress curves were generated over 20 to 30 minutes following formation of AMC product
- [AMC] v ss t + (. o - ss) [1 - exp f-k o bs J k 0 bs (2)
- the compounds used in the method of the present invention have a K j value of less than 1 micromolar
- said compounds have a K j value of less than 100 nanomolar
- the cells were washed x2 with cold RPMI-1640 by centnfugation (1000 rpm, 5 mm at 4°C) and then transferred to a sterile 15 mL centrifuge tube The number of mononuclear cells were enumerated m an improved Neubauer counting chamber
- Sufficient magnetic beads (5 / mononuclear cell), coated with goat anti-mouse IgG, were removed from their stock bottle and placed into 5 mL of fresh medium (this washes away the toxic azide preservative) The medium was removed by immobilizing the beads on a magnet and is replaced with fresh medium The beads were mixed with the cells and the suspension was incubated for 30 minutes on ice The suspension was mixed frequently The bead-coated cells were immobilized on a magnet and the remaining cells (osteoclast- ⁇ ch fraction) were decanted into a stenle 50 mL centnmge tube Fresh medium was added to the bead-coated cells to dislodge any trapped osteoclasts This wash process was repeated xlO The bead-coated cells were discarded
- the osteoclasts were enumerated m a counting chamber, using a large-bore disposable plastic pasteur pipette to charge the chamber with the sample
- the cells were pelleted by centnfugation and the density of osteoclasts adjusted to 1 5xl ⁇ 4/mL in EMEM medium, supplemented with 10% fetal calf serum and 1 7g/htre of sodium bicarbonate 3 mL ahquots of the cell suspension ( per treatment) were decanted into 15 mL centrifuge tubes These cells were pelleted by centnfugation To each tube 3 mL of the appropriate treatment was added (diluted to 50 ⁇ M in the EMEM medium) Also included were appropriate vehicle controls, a positive control (87MEM1 diluted to 100 ug/mL) and an isotype control (IgG2a diluted to 100 ug/mL) The tubes were incubated at 37°C for 30 minutes
- the TRAP positive osteoclasts were enumerated by bright-field microscopy and were then removed from the surface of the dentine by somcation Pit volumes were determined using the Nikon/Lasertec ILM21 W confocal microscope
- reaction was filtered to remove the catalyst and the filtrate was concentrated to provide
Abstract
This invention relates to the compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvate thereof, which is an inhibitor of cysteine proteases, particularly cathepsin K, and is useful in the treatment of diseases in which inhibition of bone loss or of cartilage degradation is a factor.
Description
PROTEASE INHIBITORS
FIELD OF THE INVENTION
This invention relates to a novel deuterated 4-amιno-azepan-3-one protease inhibitor. This compound is particularly an inhibitor of cysteine and senne proteases, more particularly an inhibitor of cysteine proteases. The compound of this invention even more particularly inhibits cysteine proteases of the papain superfamily, and yet more particularly cysteine proteases of the cathepsin family. In the most preferred embodiment, this invention relates to a compound which inhibits cathepsin K. Such compound is particularly useful for treating diseases in which cysteine proteases are implicated, especially diseases of excessive bone or cartilage loss, e.g., osteoporosis, periodontitis, and arthntis
BACKGROUND OF THE INVENTION
Cathepsin K is a member of the family of enzymes which are part of the papain superfamily of cysteine proteases. Cathepsins B, H, L, N and S have been described in the literature. Recently, cathepsin K polypeptide and the cDNA encoding such polypeptide were disclosed in U.S. Patent No. 5,501,969 (called cathepsin O therein). Cathepsin K has been recently expressed, purified, and charactenzed. Bossard, M. J., et al., (1996) J Biol Chem. 271, 12517-12524; Drake, F.H., et al., (1996) J Biol Chem 111, 12511-12516; Bromme, D., et al., (1996) J. Biol. Chem. Ill, 2126-2132.
Cathepsin K has been vanously denoted as cathepsin O, cathepsin X or cathepsin 02 in the literature. The designation cathepsin K is considered to be the more appropnate one (name assigned by Nomenclature Committee of the International Union of Biochemistry and Molecular Biology) Cathepsins of the papam superfamily of cysteine proteases function m the normal physiological process of protein degradation in animals, including humans, e.g., in the degradation of connective tissue. However, elevated levels of these enzymes in the body can result in pathological conditions leading to disease. Thus, cathepsins have been implicated in various disease states, including but not limited to, infections by pneumocystis carinii, trypsanoma cruzi, trypsanoma brucei brucei, and Crithidia fusiculata; as well as m schistosomiasis malaria, tumor metastasis, metachromatic leukodystrophy, muscular dystrophy, amytrophy, and the like. See International Publication Number WO 94/04172, published on March 3, 1994, and references cited therein See also European Patent Application EP 0 603 873 Al, and references cited therein. Two bacterial cysteine
proteases from P. gingivalhs, called gingipams, have been implicated in the pathogenesis of gingivitis Potempa, J , et al. (1994) Perspectives in Drug Discovery and Design, 2, 445- 458.
Cathepsin K is believed to play a causative role in diseases of excessive bone or cartilage loss. Bone is composed of a protein matrix in which spmdle- or plate-shaped crystals of hydroxyapatite are incorporated Type I Collagen represents the major structural protein of bone compnsing approximately 90% of the structural protein The remaining 10% of matrix is composed of a number of non-collagenous proteins, including osteocalcm, proteoglycans, osteopontin, osteonectin, thrombospondm, fibronectin, and bone sialoprotem. Skeletal bone undergoes remodeling at discrete foci throughout life These foci, or remodeling units, undergo a cycle consisting of a bone resorption phase followed by a phase of bone replacement
Bone resorption is carried out by osteoclasts, which are multinuclear cells of hematopoietic lineage. The osteoclasts adhere to the bone surface and form a tight sealing zone, followed by extensive membrane ruffling on their apical (i.e., resorbing) surface
This creates an enclosed extracellular compartment on the bone surface that is acidified by proton pumps m the ruffled membrane, and into which the osteoclast secretes proteolytic enzymes The low pH of the compartment dissolves hydroxyapatite crystals at the bone surface, while the proteolytic enzymes digest the protein matrix. In this way, a resorption lacuna, or pit, is formed. At the end of this phase of the cycle, osteoblasts lay down a new protein matnx that is subsequently mineralized. In several disease states, such as osteoporosis and Paget's disease, the normal balance between bone resorption and formation is disrupted, and there is a net loss of bone at each cycle. Ultimately, this leads to weakening of the bone and may result in increased fracture risk with minimal trauma The abundant selective expression of cathepsin K m osteoclasts strongly suggests that this enzyme is essential for bone resorption Thus, selective inhibition of cathepsm K may provide an effective treatment for diseases of excessive bone loss, including, but not limited to, osteoporosis, gingival diseases such as gingivitis and periodontitis, Paget's disease, hypercalcemia of malignancy, and metabolic bone disease. Cathepsin K levels have also been demonstrated to be elevated in chondroclasts of osteoarthntic synovium Thus, selective inhibition of cathepsin K may also be useful for treating diseases of excessive cartilage or matnx degradation, including, but not limited to, osteoarthntis and rheumatoid arthntis. Metastatic neoplastic cells also typically express high levels of
proteolytic enzymes that degrade the surrounding matrix Thus, selective inhibition of cathepsm K may also be useful for treating certain neoplastic diseases
It now has been discovered that a certain novel deuterated compound is a protease inhibitor, most particularly an inhibitor of cathepsin K, and that this compound is useful for treating diseases charactenzed by bone loss, such as osteoporosis and gingival diseases, such as gingivitis and periodontitis, or by excessive cartilage or matrix degradation, such as osteoarthritis and rheumatoid arthritis
SUMMARY OF THE INVENTION An object of the present invention is to provide a deuterated 4-amιno-azepan-3-one protease inhibitor, particularly an inhibitor of cysteine and serine proteases More particularly, the present invention relates to such a compound which inhibits cysteine proteases, and yet more particularly cysteine proteases of the papain superfamily Preferably, this invention relates to such a compound which inhibits cysteine proteases of the cathepsin family and most preferably, a compound which inhibits cathepsin K The compound of the present invention is useful for treating diseases which may be therapeutically modified by altering the activity of such proteases
Accordingly, in the first aspect, this invention provides a compound, 3- methylbenzofuran-2-carboxylιc acid { (S)-3-methyl- 1 -[(2,2',4-tndeuteno)-3-oxo- 1 -( 1 -oxy- pyndιne-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amιde, according to Formula I
O
- oD D H N o
-S N N
N o 0 H o
0
(I)
In another aspect, this invention provides a pharmaceutical composition compnsmg a compound according to Formula I and a pharmaceutically acceptable carrier In yet another aspect, this invention provides a method of treating diseases m which the disease pathology may be therapeutically modified by inhibiting proteases, such as cysteine and serine proteases In particular, the method includes treating diseases by inhibiting cysteine proteases, and particularly cysteine proteases of the papain superfamily More particularly, the inhibition of cysteine proteases of the cathepsin family, such as cathepsin K is descnbed
In another aspect, the compound of this invention is especially useful for treating diseases characterized by bone loss, such as osteoporosis, and gingival diseases, such as gingivitis and periodontitis, or by excessive cartilage or matrix degradation, such as osteoarthritis and rheumatoid arthritis.
DETAILED DESCRIPTION OF THE INVENTION The present invention provides a compound, 3-methylbenzofuran-2-carboxylic acid { (S)-3-methyl- 1 -[(2,2',4-trideuterio)-3-oxo- 1 -( 1 -oxy-pyridine-2-sulfonyl)-azepan-4- ylcarbamoyl] -butyl} amide, of Formula (I):
D 0
D H
0D O
N
+ S N N
N 0 0 H o"
(I)
or a pharmaceutically acceptable salt, hydrate or solvate thereof.
The present invention includes all hydrates, solvates, complexes, polymorphs and prodrugs of the compound of Formula (I). Prodrugs are any covalently bonded compounds which release the active parent drug according to Formula (I) in vivo. Prodrugs of the compound of the present invention include ketone derivatives, specifically ketals or hemiketals.
All forms of isomers resulting from the presence of a chiral center in the inventive compound, including enantiomers and diastereomers, are intended to be covered herein. The inventive compound may be used as a racemic mixture, an enantiomerically enriched mixture, or the racemic mixture may be separated using well-known techniques and an individual enantiomer may be used alone.
In the event that the present compound may exist in tautomeric forms, such as keto- enol tautomers, each tautomeric form is contemplated as being included within this invention whether existing in equilibrium or predominantly in one form.
Compared to the corresponding 5 and 6 membered ring compounds, the 7 membered ring compound of the present invention is configurationally more stable at the carbon center alpha to the ketone.
Definitions
Abbreviations and symbols commonly used m the peptide and chemical arts are used herein to descnbe the compounds of the present invention In general, the ammo acid abbreviations follow the IUPAC-IUB Joint Commission on Biochemical Nomenclature as described m Eur J Biochem , 158, 9 (1984) In particular, throughout this application, m- CPBA means .wetα-chloroperoxybenzoic acid, Boc means terf-butoxycarbonyl, EDC means l-(3-dιmethylammopropyl)-3-ethylcarbodnmιde hydrochlonde, DMSO means methyl sulfoxide, and TEA means tnethylamine
Method of Preparation
The compound of the Formula (I) is generally prepared according to Scheme
1 The individual diastereomers of 3-methylbenzofuran-2-carboxylιc acid {(S)-3- methyl-1 -[(2,2',4-tndeuteπo)3-oxo- 1 -( 1 -oxy-pyπdιne-2-sulfonyl)-azepan-4- ylcarbamoyl] -butyl} amide 10 and 11 may be prepared as outlined in Scheme 1 Alkylation of allyl-carbamic acid benzyl ester (1) with 5-bromo- 1 -pentene in the presence of a base such as sodium hydnde provides the diene 2 Treatment of diene
2 with bιs(tπcyclohexylphosphme)benzylιdme ruthenium (IV) dichlonde developed by Grubbs provides the 2,3,4,7-tetrahydro-azepιne-l-carboxylιc acid benzyl ester 3 Epoxidation of azepme 3 may be effected with standard oxidizing agents common to the art such as -CPBA to provide epoxide 4 Nucleophilic epoxide nng opening of 4 may be effected with a reagent such as sodium azide to provide the azido alcohol (not shown)
Scheme 1
H O N O N O N 0 O
OH
NH, d. e f. 9
0 N O N 0 0
OH
OH
NH,
S
.. o
OH
O"
S S
.♦ ° . 0
D H D H N N
I, m D
S ,. O . O
10 11
Reagents and Conditions: a.) NaH, 5-bromo- 1 -pentene, DMF; b.) bis(tπcyclohexylphosphme)benzyhdine ruthenium (IV) dichloride, CH2C12: c.) /w-CPBA, CH2C12; d.) NaN,, CH,OH, H20, NH4C1; e.) 1 ,3-propanedithiol, TEA, methanol; f.) N-Boc-leucine, EDC, CH2C12; g.) 10% Pd/C, H2; h.) 2-pyridinesulphonyl chloπde-N-oxide. sat. NaHCO,, CH2C12; i.) 4 N HCl/dioxane, methanol; j.) 3-methylbenzofuran-2-carboxylic acid, EDC, CH2C12; k.) pyridine sulfur trioxide complex, DMSO, TEA; 1.) CD3OD;D20 (10:1 ), TEA; m.) HPLC separation.
The intermediate azido alcohol may be reduced to the ammo alcohol 5 under conditions common to the art such as 1 ,3-propanedithiol and tnethylamme m methanol or with tπphenylphosphine in tetrahydrofuran and water. Acylation of 5 may be effected with an acid such as N-Boc-leucine in the presence of a coupling agent such as EDC Removal of the benzyl oxycarbonyl protecting group with hydrogen gas in the presence of 10% Pd/C provides the amine 6 Treatment of the amme 6 with 2-pyndmesulphonyl chlonde N-oxide m the presence of saturated sodium bicarbonate and CH2C12 followed by removal of the rert-butoxycarbonyl protecting group under acidic conditions provides 7 Coupling of 7 with 3-methylbenzofuran-2-carboxyhc acid may be effected with a coupling agent such as EDC to provide intermediate alcohol 8. Alcohol 8 may be oxidized with an oxidant such as sulfur tπoxide pyndine complex in DMSO and tnethylamme to provide the ketone 9 as a mixture of diastereomers. Treatment of ketone 9 with triethylamine in CD^OD D20 at reflux provides the deuterated analog as a mixture of diastereomers which are separated by
HPLC to provide the deuterated compounds 10 and 11
The starting materials used herein are commercially available or are prepared by routine methods well known to those of ordinary skill m the art and can be found in standard reference books, such as the COMPENDIUM OF ORGANIC SYNTHETIC
METHODS, Vol. I-VI (published by Wiley-Interscience). Coupling methods to form amide bonds herein are generally well-known in the art
The methods of peptide synthesis generally set forth by Bodansky et al., THE PRACTICE OF PEPTIDE SYNTHESIS, Spnnger-Verlag, Berlin, 1984, E. Gross and J. Meienhofer, THE PEPTIDES, Vol. 1 , 1-284 (1979); and J.M. Stewart and J.D. Young, SOLID PHASE PEPTIDE SYNTHESIS, 2d Ed., Pierce Chemical Co., Rockford, 111., 1984, are generally illustrative of the technique and are incorporated herein by reference.
Synthetic methods useful in preparing the compound of this invention frequently employ protective groups to mask a reactive functionality or minimize unwanted side reactions. Such protective groups are described generally in Green, T.W, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, John Wiley & Sons, New York (1981). The term "ammo protecting groups" generally refers to the Boc, acetyl, benzoyl, Fmoc and Cbz groups and denvatives thereof as known to the art Methods for protection and deprotection, and replacement of an amino protecting group with another moiety are well known.
Acid addition salts of the compound of Formula (I) are prepared in a standard manner m a suitable solvent from the parent compound and an excess of an acid, such as
hydrochloric, hydrobromic, hydrofluoric, sulfunc, phosphoric, acetic, tnfluoroacetic, maleic, succmic or methanesulfonic acid
Novel Intermediate The present invention also provides a novel intermediate, 3-methylbenzofuran-2- carboxyhc acid { (S)-3 -methyl- 1 -[3-hydroxy- 1 -( 1 -oxy-pyπdme-2-sulfonyl)-azepan-4- ylcarbamoyl]-butyl}amιde (8-Scheme-l), of Formula (II), useful in the synthesis of the compound of Formula (I) according to Scheme 1
OH
0 H N o
+ S N N
N 0 0 H
O
0
(II)
Process for Synthesis of Inventive Compounds
Refernng to Scheme 1 herein above, the present invention provides a process for the synthesis of compounds of Formula (I) comprising the step of oxidizing the appropriate compound of Formula (II) with an oxidant to provide the compound of Formula (I) as a mixture of diastereomers. Preferably the oxidant is sulfur tnoxide pyndine complex m DMSO and tnethylamme.
Refernng to Scheme 1 , the present invention also provides a process for the synthesis of deuterated compounds of Formula (I) Specifically, when a deuterated isomer is desired, an additional step, following the oxidation step, of deuteratmg the protonated isomer with a deuteratmg agent to provide the deuterated compound of Formula (I) as a mixture of diastereomers is added to the synthesis. Preferably, the deuteratmg agent is CD3OD:D20 (10: 1) in tnethylamme. The process further comprises the step of separating the diasteromers of Formula
(I) by separating means, preferably by high presssure liquid chromatography (HPLC)
Utility of the Present Invention
The present compound of Formula I exhibits superior chiral stability compared to the protonated isomer.
This invention also provides a pharmaceutical composition which comprises a compound according to Formula (I) and a pharmaceutically acceptable earner, excipient or diluent Accordingly, the compound of Formula (I) may be used in the manufacture of a medicament Pharmaceutical compositions of the compound of Formula (I) prepared as hereinbefore described may be formulated as solutions or lyophihzed powders for parenteral administration Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable earner prior to use The liquid formulation may be a buffered, isotonic, aqueous solution Examples of suitable diluents are normal isotonic saline solution, standard 5% dextrose in water, or buffered sodium or ammonium acetate solution Such formulation is especially suitable for parenteral administration, but may also be used for oral administration or contained in a metered dose inhaler or nebulizer for insufflation It may be desirable to add excipients such as polyvmylpyrrohdone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride, or sodium citrate Alternately, this compound may be encapsulated, tableted, or prepared in an emulsion or syrup for oral administration Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or steaπc acid, talc, pectin, acacia, agar or gelatin Liquid earners include syrup, peanut oil, olive oil, saline and water The carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax The amount of solid carrier varies but, preferably, will be between about 20 mg to about 1 g per dosage unit The pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulating, and compressing, when necessary, for tablet forms, or milling, mixing and filling for hard gelatin capsule forms When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion or an aqueous or non-aqueous suspension Such a liquid formulation may be administered directly or filled into a soft gelatin capsule
For rectal administration, the compound of this invention may also be combined with excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols and molded into a suppository
The compound of Formula (I) is useful as a protease inhibitor, particularly as an inhibitor of cysteine and serme proteases, more particularly as an inhibitor of cysteine proteases, even more particularly as an inhibitor of cysteine proteases of the papain
superfamily, yet more particularly as an inhibitor of cysteine proteases of the cathepsin family, most particularly as an inhibitor of cathepsin K The present invention also provides useful compositions and formulations of said compound, including pharmaceutical compositions and formulations of said compound The present compound is useful for treating diseases in which cysteine proteases are implicated, including infections by pneumocystis carinii, trypsanoma cruzi, trypsanoma brucei, and Crithidia fusiculata, as well as in schistosomiasis, malana, tumor metastasis, metachromatic leukodystrophy, muscular dystrophy, amytrophy, and especially diseases in which cathepsin K is implicated, most particularly diseases of excessive bone or cartilage loss, including osteoporosis, gingival disease including gingivitis and penodontitis, arthritis, more specifically, osteoarthritis and rheumatoid arthntis, Paget's disease, hypercalcemia of malignancy, and metabolic bone disease
Metastatic neoplastic cells also typically express high levels of proteolytic enzymes that degrade the sunounding matrix, and certain tumors and metastatic neoplasias may be effectively treated with the compound of this invention
The present invention also provides methods of treatment of diseases caused by pathological levels of proteases, particularly cysteine and serine proteases, more particularly cysteine proteases, even more particularly cysteine proteases of the papain superfamily, yet more particularly cysteine proteases of the cathepsin family, which methods comprise admmistenng to an animal, particularly a mammal, most particularly a human in need thereof the compound of the present invention The present invention especially provides methods of treatment of diseases caused by pathological levels of cathepsin K, which methods comprise admmistenng to an animal, particularly a mammal, most particularly a human m need thereof, an inhibitor of cathepsin K, including the compound of the present invention The present invention particularly provides methods for treating diseases in which cysteine proteases are implicated, including infections by pneumocystis cannn, trypsanoma cruzi, trypsanoma brucei, and Cnthidia fusiculata, as well as in schistosomiasis, malaria, tumor metastasis, metachromatic leukodystrophy, muscular dystrophy, amytrophy, and especially diseases m which cathepsm K is implicated, most particularly diseases of excessive bone or cartilage loss, including osteoporosis, gingival disease including gingivitis and periodontitis, arthritis, more specifically, osteoarthritis and rheumatoid arthritis, Paget's disease, hypercalcemia of malignancy, and metabolic bone disease
This invention further provides a method for treating osteoporosis or inhibiting bone loss which compnses internal administration to a patient of an effective amount of the compound of Formula (I), alone or m combination with other inhibitors of bone resorption, such as bisphosphonates (i.e., allendronate), hormone replacement therapy, anti-estrogens, or calcitonm In addition, treatment with the compound of this invention and an anabolic agent, such as bone morphogenic protein, lproflavone, may be used to prevent bone loss or to increase bone mass.
In accordance with this invention, an effective amount of the compound of Formula (I) is administered to inhibit the protease implicated in a particular condition or disease Of course, this dosage amount will further be modified according to the type of administration of the compound For example, for acute therapy, parenteral administration of the compound of Formula (I) is preferred An intravenous infusion of the compound m 5% dextrose in water or normal salme, or a similar formulation with suitable excipients, is most effective, although an intramuscular bolus injection is also useful Typically, the parenteral dose will be about 0.01 to about 100 mg/kg, preferably between 0 1 and 20 mg/kg, in a manner to maintain the concentration of drug in the plasma at a concentration effective to inhibit cathepsin K. The compound is administered one to four times daily at a level to achieve a total daily dose of about 0 4 to about 400 mg/kg day. The precise amount of the inventive compound which is therapeutically effective, and the route by which such compound is best administered, is readily determined by one of ordinary skill in the art by comparing the blood level of the agent to the concentration required to have a therapeutic effect
Prodrugs of the compound of the present invention may be prepared by any suitable method Where the prodrug moiety is a ketone functionality, specifically ketals and/or hemiacetals, the conversion may be effected m accordance with conventional methods
The compound of this invention may also be administered orally to the patient, in a manner such that the concentration of drug is sufficient to inhibit bone resorption or to achieve any other therapeutic indication as disclosed herein. Typically, a pharmaceutical composition containing the compound is administered at an oral dose of between about 0.1 to about 50 mg/kg in a manner consistent with the condition of the patient Preferably the oral dose would be about 0.5 to about 20 mg/kg
No unacceptable toxicological effects are expected when compounds of the present invention are administered in accordance with the present invention
Biological Assays The compound of this invention may be tested m one of several biological assays to determine the concentration of the compound which is required to have a given pharmacological effect
Determination of cathepsin K proteolytic catalytic activity All assays for cathepsin K were carried out with human recombinant enzyme
Standard assay conditions for the determination of kinetic constants used a fluorogemc peptide substrate, typically Cbz-Phe-Arg-AMC, and were determined in 100 mM Na acetate at pH 5 5 containing 20 mM cysteine and 5 mM EDTA Stock substrate solutions were prepared at concentrations of 10 or 20 mM in DMSO with 20 μM final substrate concentration in the assays. All assays contained 10% DMSO Independent expenments found that this level of DMSO had no effect on enzyme activity or kinetic constants. All assays were conducted at ambient temperature. Product fluorescence (excitation at 360 nM; emission at 460 nM) was monitored with a Perceptive Biosystems Cytofluor II fluorescent plate reader. Product progress curves were generated over 20 to 30 minutes following formation of AMC product
Inhibition studies
Potential inhibitors were evaluated using the progress curve method. Assays were carried out in the presence of vanable concentrations of test compound Reactions were initiated by addition of enzyme to buffered solutions of inhibitor and substrate Data analysis was conducted according to one of two procedures depending on the appearance of the progress curves in the presence of inhibitors For those compounds whose progress curves were linear, apparent inhibition constants {Kι app) were calculated according to equation 1 (Brandt et al., Bwchemitsry, 1989, 28, 140)
v = VmA / [Ka(l + VKlt app) +A] ( 1 )
where v is the velocity of the reaction with maximal velocity Vm , A is the concentration of substrate with Michaehs constant of Ka, and I is the concentration of inhibitor
For those compounds whose progress curves showed downward curvature characteristic of time-dependent inhibition, the data from individual sets was analyzed to give k0 >s according to equation 2
[AMC] = vss t + (. o - ss) [1 - exp f-kobs J k0bs (2)
where [AMC] is the concentration of product formed over time t, vβ is the initial reaction velocity, and vss is the final steady state rate Values for k0bs were then analyzed as a linear function of inhibitor concentration to generate an apparent second order rate constant (k0bs / inhibitor concentration or k0bs / [I]) describing the time-dependent inhibition A complete discussion of this kinetic treatment has been fully described (Mornson et al , Ad\
Enzvmol Relat Areas Mol Biol , 1988, 61, 201)
One skilled in the art would consider any compound with a Kj of less than 50 micromolar to be a potential lead compound Preferably, the compounds used in the method of the present invention have a Kj value of less than 1 micromolar Most preferably, said compounds have a Kj value of less than 100 nanomolar
Human Osteoclast Resorption Assay
Ahquots of osteoclastoma-denved cell suspensions were removed from liquid nitrogen storage, warmed rapidly at 37°C and washed xl in RPMI-1640 medium by centnfugation (1000 rpm, 5 min at 4°C) The medium was aspirated and replaced with munne anti-HLA-DR antibody, diluted 1 3 in RPMI-1640 medium, and incubated for 30 minutes on ice The cell suspension was mixed frequently
The cells were washed x2 with cold RPMI-1640 by centnfugation (1000 rpm, 5 mm at 4°C) and then transferred to a sterile 15 mL centrifuge tube The number of mononuclear cells were enumerated m an improved Neubauer counting chamber
Sufficient magnetic beads (5 / mononuclear cell), coated with goat anti-mouse IgG, were removed from their stock bottle and placed into 5 mL of fresh medium (this washes away the toxic azide preservative) The medium was removed by immobilizing the beads on a magnet and is replaced with fresh medium The beads were mixed with the cells and the suspension was incubated for 30 minutes on ice The suspension was mixed frequently The bead-coated cells were immobilized on a magnet and the remaining cells (osteoclast-πch fraction) were decanted into a stenle 50 mL centnmge tube Fresh medium was added to the bead-coated cells to
dislodge any trapped osteoclasts This wash process was repeated xlO The bead-coated cells were discarded
The osteoclasts were enumerated m a counting chamber, using a large-bore disposable plastic pasteur pipette to charge the chamber with the sample The cells were pelleted by centnfugation and the density of osteoclasts adjusted to 1 5xlθ4/mL in EMEM medium, supplemented with 10% fetal calf serum and 1 7g/htre of sodium bicarbonate 3 mL ahquots of the cell suspension ( per treatment) were decanted into 15 mL centrifuge tubes These cells were pelleted by centnfugation To each tube 3 mL of the appropriate treatment was added (diluted to 50 μM in the EMEM medium) Also included were appropriate vehicle controls, a positive control (87MEM1 diluted to 100 ug/mL) and an isotype control (IgG2a diluted to 100 ug/mL) The tubes were incubated at 37°C for 30 minutes
0 5 mL ahquots of the cells were seeded onto stenle dentine slices in a 48-well plate and incubated at 37°C for 2 hours Each treatment was screened in quadruplicate The slices were washed in six changes of warm PBS (10 mL / well in a 6-well plate) and then placed into fresh treatment or control and incubated at 37°C for 48 hours The slices were then washed in phosphate buffered saline and fixed in 2% glutaraldehyde (in 0 2M sodium cacodylate) for 5 minutes, following which they were washed in water and incubated in buffer for 5 minutes at 37°C The slices were then washed in cold water and incubated in cold acetate buffer / fast red garnet for 5 minutes at 4°C Excess buffer was aspirated, and the slices were air dned following a wash in water
The TRAP positive osteoclasts were enumerated by bright-field microscopy and were then removed from the surface of the dentine by somcation Pit volumes were determined using the Nikon/Lasertec ILM21 W confocal microscope
Examples In the following synthetic examples, unless otherwise indicated, all of the starting materials were obtained from commercial sources Without further elaboration, it is believed that one skilled m the art can, using the preceding description, utilize the present invention to its fullest extent These Examples are given to illustrate the invention, not to limit its scope Reference is made to the claims for what is reserved to the inventors hereunder
Example 1
Preparation of 3-Methylbenzofuran-2-carboxyhc acid j (S)-3-methyl-l-r(2.2',4-tndeuteπo)- 3-oxo-l -( 1 -oxy-pyndιne-2-sulfonyl)-azepan-4-ylcarbamoyl1 butyl } amide
a.) Allyl-pent-4-enyl-carbamιc acid benzyl ester
To a suspension of NaH (1.83 g, 76.33 mmol of 90% NaH) in DMF was added allyl-carbamic acid benzyl ester (7.3 g, 38.2 mmol) in a dropwise fashion The mixture was stirred at room temperature for approximately 10 minutes whereupon 5 -bromo-1 -pentene (6.78 mL, 57.24 mmol) was added in a dropwise fashion. The reaction was heated to 40°C for approximately 4 hours whereupon the reaction was partitioned between dichloromethane and water. The organic layer was washed with water (2x's), bnne, dried (MgS04), filtered and concentrated. Column chromatography of the residue (10% ethyl acetate:hexanes) provided 10.3 grams of the title compound as an oil: MS(EI) 260 (M+H+).
b ) 2,3,4,7-Tetrahydro-azepme-l-carboxyhc acid benzyl ester
To a solution of compound of Example la (50 g) in dichloromethane was added bιs(tncyclohexylphosphιne)benzylιdme ruthenium (IV) dichloride (5.0 g). The reaction was heated to reflux until complete as determined by TLC analysis. The reaction was concentrated in vacuo. Column chromatography of the residue (50% dιchloromethane:hexanes) gave 35 g of the title compound: MS(EI) 232 (M+H+)
c.) 8-Oxa-3-aza-bιcyclo[5.1.0]octane-3-carboxyhc acid benzyl ester
To a solution of the compound of Example lb (35 g, 1.5 mol) in CH Cl- was added w-CPBA (78 g, 0.45 mol). The mixture was stirred overnight at room temperature whereupon it was filtered to remove the solids The filtrate was washed with water and saturated NaHC03 (several times). The organic layer was dried (MgS04), filtered and concentrated to give 35 g of the title compound which was of sufficient purity to use in the next step: MS(EI) 248 (M+H+), 270 (M+Na+).
d. 4-Azιdo-3-hydroxy-azepane-l-carboxyhc acid benzyl ester
To a solution of the epoxide from Example lc (2.0 g, 8.1 mmol) in methanokwater
(8.1 solution) was added NH4C1 (1.29 g, 24.3 mmol) and sodium azide (1.58 g, 24.30 mmol). The reaction was heated to 65-75°C until complete consumption of the starting epoxide was observed by TLC analysis. The majonty of the solvent was removed in vacuo and the remaining solution was partitioned between ethyl acetate and pH 4 buffer. The organic layer was washed with sat. NaHC03, water, brine dried (MgS04), filtered and
concentrated Column chromatography (20% ethyl acetate:hexanes) of the residue provided 1.3 g of the title compound- MS(EI) 291 (M+H+) plus 0.14 g of trans-4-hydroxy-3-azιdo- hexahydro- 1 H-azepme
e ) 4-Amιno-3-hydroxy-azepane-l-carboxylιc acid benzyl ester
To a solution of the azido alcohol of Example Id (1 1 g, 3.79 mmol) m methanol was added tnethylamme (1.5 mL, 1 1.37 mmol) and 1,3-propanedithiol (1.1 mL, 1 1.37 mmol) The reaction was stirred until complete consumption of the starting material was observed by TLC analysis whereupon it was concentrated in vacuo. Column chromatography of the residue (20% methanohdichloromethane) provided 0.72 g of the title compound: MS(EI) 265 (M+H+).
f.) 4-((S)-2-tert-Butoxycarbonylamιno-4-methyl-pentanoylamιno)-3-hydroxy-azepan- 1 - carboxyhc acid benzyl ester To a solution of the ammo alcohol of Example le (720 mg, 2.72 mmol) m CH2C12 was added EDC (521 mg), HOBt (368 mg) and N-Boc-leucme (630 mg). The reaction was maintained at room temperature until complete consumption of the starting matenal was observed by TLC analysis. The reaction was diluted with ethyl acetate and washed with IN HC1. sat. K2C03, water, bnne, dried (MgS04), filtered and concentrated. Column chromatography of the residue (3% methanol: dichloromethane) gave 1.0 g of the title compound: MS(EI) 478 (M+H+).
g.) [(S)-l-(3-Hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-carbamιc acid ten butyl ester To a solution of the compound of Example If (1.0 g) and 10% Pd/C (catalytic) in ethyl acetate:methanol (2: 1 solution) was attached a balloon of hydrogen. The reaction was stirred until complete consumption of the starting material was observed by TLC analysis.
The reaction was filtered to remove the catalyst and the filtrate was concentrated to provide
0.82 g of the title compound: MS(EI) 344 (M+H+).
h.) { (S)-l -[3-Hydroxy- 1 -( 1 -oxy-pyπdme-2-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl- butyl}-carbamιc acid tert-butyl ester
Generation of 2-pyπdmesulfonylchloπde-N-oxιde: To a 0°C solution of 2- mercaptopyπdme-N-oxide (2.23 g, 17.55 mmol) in 9M HC1 (33 mL) was bubbled chlonne gas for approximately 90 minutes. The dissolved chlorine was removed under vacuum at
0°C.
To a solution of [(S)-l-(3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]- carbarmc acid tert butyl ester of Example lg (2.5 g, 7.28 mmol) in CH2C12 (100 mL) and sat. NaHC03 (400 mL) was added the solution of 2-pyndιnesulfonylchlorιde-N-oxιde (27 mL, 102 mg/mL) dropwise in portions As the addition proceeds additional sat. NaHC03 is added in order to maintain the pH at approximately 8-9 Upon complete addition of the sulfonylchloπde the reaction is stirred for an additional hour whereupon the organic layer was removed and washed with brme. The organic layer was evaporated and the residue chromatographed (5% methanobdichloromethane) to provide 2.5 g of the title compound: MS (El) 500 (M+H+).
l.) (S)-2-Amιno-4-methyl-pentanoιc acιd-[3-hydroxy- 1 -( 1 -oxy-pyπdιne-2-sulfonyl)- azepan-4-yl] -amide
To a solution of {(S)-l-[3-hydroxy-l -(l-oxy-pyndme-2-sulfonyl)-azepan-4- ylcarbamoyl]-3-methyl-butyl}-carbamιc acid terf-butyl ester of Example lh (2.0 g) in methanol (20 mL) was added 4 M HCl m dioxane (20 mL) The reaction was stirred at room temperature for 1.5 hours whereupon it was concentrated to provide 1.8 g of the title compound: MS (El) 400 (M+Hτ).
j.) 3-Methylbenzofuran-2-carboxyhc acid {(S)-3-methyl-l-[3-hydroxy-l-(l-oxy- pyndιne-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amιde
To a solution of the compound of Example h (0.32 g, 0.73 mmol) in CH2C12 was added tnethylamme (1.09 mmol), EDC (0.73 mmol), HOBt (0.73 mmol) and 3- methylbenzofuran-2-carboxylιc acid (0.73 mmol). The reaction was stirred until complete by TLC analysis. Workup and column chromatography of the residue (10% methanol: dichloromethane) gave 0.27 g of the title compound: MS(EI) 558 (M+)
k.) 3-Methylbenzofuran-2-carboxyhc acid {(S)-3-methyl-l-[3-oxo-l-(l-oxy-pyndιne-2- sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amιde
To a solution of the alcohol of Example lj (0.27 g, 0.48 mmol) in DMSO was added TEA (0.4 mL) and pyndine sulfur tnoxide complex (229 mg). The reaction was stirred at room temperature for approximately 2 hours whereupon it was partitioned between ethyl acetate and water. The organic layer was washed with brine, dned, filtered and concentrated. Column chromatography of the residue (10% CH,OH:CH-Cl-) provided
180 mg of the title compound as a mixture of diastereomers: Η NMR (CDC13): δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.5 (d, 3H), 2.1 (m, IH), 3.8 (q, IH); 4.0 (m, IH), 4,5 (t,
IH), 4.7 (m, IH), 5.0 (m, IH), 7.4-8.0 (m, 6H), 8.1-8.2 (m, 2H); MS(EI): 556 (M+,100%) .
1.) 3-Methyl-benzofuran-2-carboxyhc acid {(S)-3-methyl-l -[(2,2',4-tndeuteπo)-3-oxo-
1 -( 1 -oxy-pyrιdme-2-sulfonyl)-azepan-4-ylcarbamoyl] butyl } amide
To a solution of 3-methylbenzofuran-2-carboxylιc acid {(S)-3-methyl-l-[3-oxo-l- (l-oxy-pyndme-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl} amide (0.03 g) ιn D20:CD3OD (0 4-4 mL) was added tnethylamme (0 04 mL) The reaction was heated to reflux for 2 hours whereupon it was concentrated and dried under vacuum The residue was then redissolved in the same mixture and heated to reflux overnight The reaction was concentrated and the residue purified by column chromatography to provide the title compound The diastereomers are separated by HPLC
The above specification and Example fully disclose how to make and use the compound of the present invention. However, the present invention is not limited to the particular embodiments described hereinabove, but includes all modifications thereof within the scope of the following claims The various references to journals, patents and other publications which are cited herein comprise the state of the art and are incorporated herein by reference as though fully set forth.
Claims
What is claimed is:
A compound according to Formula (I):
(I)
known as 3-methylbenzofuran-2-carboxylic acid {(S)-3-methyl-l-[(2,2',4-trideuterio)-3- oxo-1 -( 1 -oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl] -butyl } amide, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
2. A pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier, excipient or diluent.
3. A method of inhibiting a protease selected from the group consisting of a cysteine protease and a serine protease, comprising administering to a patient in need thereof an effective amount of a compound according to Claim 1.
4. A method according to Claim 3 wherein said protease is a cysteine protease.
5. A method according to Claim 4 wherein said cysteine protease is cathepsin K.
7. A method of treating a disease characterized by bone loss comprising inhibiting said bone loss by administering to a patient in need thereof an effective amount of a compound according to Claim 1.
8. A method according to Claim 7 wherein said disease is osteoporosis.
9. A method according to Claim 7 wherein said disease is periodontitis.
10. A method according to Claim 7 wherein said disease is gingivitis.
1 1. A method of treating a disease characterized by excessive cartilage or matrix degradation comprising inhibiting said excessive cartilage or matrix degradation by administering to a patient in need thereof an effective amount of a compound according to Claim 1.
12. A method according to Claim 11 wherein said disease is osteoarthritis.
13. A method according to Claim 1 1 wherein said disease is rheumatoid arthritis.
14. A process for the synthesis of the compound of Formula (I):
(I)
comprising the steps:
(a) of oxidizing the compound of Formula (II):
OH
— o -- N o
-S- N N " ^ - ^
O -=-
(ii) with an oxidant to provide the protonated isomer of the compound of Formula (I) as a mixture of diastereomers; (b) deuterating the protonated isomer with a deuterating agent to provide the compound of Formula (I) as a mixture of diastereomers.
15. The process of Claim 14 wherein the oxidant is sulfur trioxide pyridine complex in DMSO and triethylamine.
16. The process of Claim 14 wherein the deuterating agent is CD3θD:D2θ (10: 1) in triethylamine.
17. The process of Claim 14 further comprising the step of separating the diasteromers by separating means.
18. The process of Claim 17 wherein said separating means is high presssure liquid chromatography (HPLC).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16456199P | 1999-11-10 | 1999-11-10 | |
US164561P | 1999-11-10 | ||
PCT/US2000/030682 WO2001034566A2 (en) | 1999-11-10 | 2000-11-08 | Protease inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1351930A2 true EP1351930A2 (en) | 2003-10-15 |
EP1351930A4 EP1351930A4 (en) | 2004-09-15 |
Family
ID=22595065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00977056A Withdrawn EP1351930A4 (en) | 1999-11-10 | 2000-11-08 | Protease inhibitors |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1351930A4 (en) |
JP (1) | JP2003533432A (en) |
AU (1) | AU1474701A (en) |
WO (1) | WO2001034566A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030144175A1 (en) | 1998-12-23 | 2003-07-31 | Smithkline Beecham Corporation | Protease inhibitors |
KR100630986B1 (en) * | 1998-12-23 | 2006-10-09 | 스미스클라인 비참 코포레이션 | Protease Inhibitors |
US6534498B1 (en) | 1999-11-10 | 2003-03-18 | Smithkline Beecham Corporation | Protease inhibitors |
EP1232155A4 (en) | 1999-11-10 | 2002-11-20 | Smithkline Beecham Corp | Protease inhibitors |
JP2003513972A (en) | 1999-11-10 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | Protease inhibitor |
PL357727A1 (en) | 2000-03-21 | 2004-07-26 | Smithkline Beecham Corporation | Protease inhibitors |
CO5280093A1 (en) * | 2000-04-18 | 2003-05-30 | Smithkline Beecham Corp | TREATMENT METHODS |
CN105288305A (en) * | 2015-11-30 | 2016-02-03 | 延欣虹 | Pharmaceutical composition for curing oral excessive inflammation and gingival pain and swelling and preparation method of pharmaceutical composition |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998005336A1 (en) * | 1996-08-08 | 1998-02-12 | Smithkline Beecham Corporation | Inhibitors of cysteine protease |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100630986B1 (en) * | 1998-12-23 | 2006-10-09 | 스미스클라인 비참 코포레이션 | Protease Inhibitors |
-
2000
- 2000-11-08 AU AU14747/01A patent/AU1474701A/en not_active Abandoned
- 2000-11-08 JP JP2001536515A patent/JP2003533432A/en not_active Withdrawn
- 2000-11-08 WO PCT/US2000/030682 patent/WO2001034566A2/en not_active Application Discontinuation
- 2000-11-08 EP EP00977056A patent/EP1351930A4/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998005336A1 (en) * | 1996-08-08 | 1998-02-12 | Smithkline Beecham Corporation | Inhibitors of cysteine protease |
Non-Patent Citations (1)
Title |
---|
See also references of WO0134566A2 * |
Also Published As
Publication number | Publication date |
---|---|
AU1474701A (en) | 2001-06-06 |
WO2001034566A3 (en) | 2003-07-31 |
JP2003533432A (en) | 2003-11-11 |
EP1351930A4 (en) | 2004-09-15 |
WO2001034566A2 (en) | 2001-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998008802A1 (en) | Inhibitors of cysteine protease | |
US6596715B1 (en) | Protease inhibitors | |
WO2001034565A2 (en) | Protease inhibitors | |
US6534498B1 (en) | Protease inhibitors | |
WO2001034566A2 (en) | Protease inhibitors | |
WO2000029408A1 (en) | Morpholino-ethoxybenzofuran protease inhibitors | |
EP1229915A1 (en) | Protease inhibitors | |
WO2001034154A1 (en) | Protease inhibitors | |
EP1231921A1 (en) | Protease inhibitors | |
WO2001034155A1 (en) | Protease inhibitors | |
EP1229911A1 (en) | Protease inhibitors | |
US6583137B1 (en) | Protease inhibitors | |
WO2001034157A1 (en) | Protease inhibitors | |
WO2001034159A1 (en) | Protease inhibitors | |
US20040157828A1 (en) | Protease inhibitors | |
US20020082426A1 (en) | Protease inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020603 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040729 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20041012 |